Macrogenics (MGNX) Gross Margin (2020 - 2025)
Macrogenics (MGNX) posted quarterly Gross Margin of 100.0% for Q4 2025, up 58.0% year-over-year from 63.29% in Q4 2024, and little changed quarter-over-quarter from 100.0% in Q3 2025.
Macrogenics (MGNX) Gross Margin (2020 - 2025) Analysis & Trends
Macrogenics (MGNX) has reported Gross Margin for 6 consecutive years, with 100.0% the latest figure, recorded in Q4 2025.
- In Q4 2025, Gross Margin rose 58.0% year-over-year to 100.0%; the TTM figure through Dec 2025 stood at 100.0% (up 50.0% YoY), while the FY2025 annual figure was 100.0%, up 56.0% from the prior year.
- Gross Margin was little changed at 100.0% in Q4 2025 per MGNX's latest filing, from 100.0% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q1 2025 and bottomed at 89.37% in Q3 2021.
- Historically, Gross Margin has averaged 98.2% across 5 years, with a median of 99.48% in 2023.
- Annual changes were most pronounced in 2021 — Gross Margin sank 1063 bps — and 2022, when it soared 654 bps.
- Macrogenics' Gross Margin stood at 93.31% in 2021, then increased by 7 bps to 99.84% in 2022, then retreated by 1 bps to 98.48% in 2023, then rose by 1 bps to 99.42% in 2024, then gained by 1 bps to 100.0% in 2025.
- Business Quant data shows MGNX's Gross Margin at 100.0% in Q4 2025, 100.0% in Q3 2025, and 100.0% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100.00% |
| Sep 30, 2025 | 100.00% |
| Jun 30, 2025 | 100.00% |
| Mar 31, 2025 | 100.00% |
| Dec 31, 2024 | 99.42% |
| Sep 30, 2024 | 99.85% |
| Jun 30, 2024 | 98.37% |
| Mar 31, 2024 | 97.03% |
| Dec 31, 2023 | 98.48% |
| Sep 30, 2023 | 99.18% |
| Jun 30, 2023 | 98.04% |
| Mar 31, 2023 | 99.54% |
| Dec 31, 2022 | 99.84% |
| Sep 30, 2022 | 92.79% |
| Jun 30, 2022 | 99.31% |
| Mar 31, 2022 | 99.57% |
| Dec 31, 2021 | 93.31% |
| Sep 30, 2021 | 89.37% |
| Jun 30, 2021 | 99.93% |
| Mar 31, 2021 | 99.90% |